Top

Published in:

Open Access 03-11-2023 | Vaccination | Original Communication

SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose

Authors: Massimiliano Di Filippo, Diana Ferraro, Paolo Ragonese, Luca Prosperini, Giorgia Teresa Maniscalco, Antonio Gallo, Paola Cavalla, Lorena Lorefice, Viviana Nociti, Elena Di Sabatino, Marinella Clerico, Clara Guaschino, Marta Radaelli, Roberta Fantozzi, Fabio Buttari, Alice Laroni, Alberto Gajofatto, Massimiliano Calabrese, Simona Malucchi, Damiano Paolicelli, Giovanna De Luca, Valentina Tomassini, Roberta Lanzillo, Marcello Moccia, Claudio Solaro, Eleonora Cocco, Claudio Gasperini, Carla Tortorella, the RIREMS (Rising Researchers in MS) group

Published in: Journal of Neurology | Issue 1/2024

Abstract

Background

COVID-19 vaccines have been recommended to people with multiple sclerosis (pwMS) and, to ensure durable immunity, a third booster dose has been administered in several countries. Data about potential risks associated with the third booster dose in pwMS, such as vaccine-triggered disease exacerbations, are still scarce.

Objective

To investigate whether the administration of a third booster dose of mRNA COVID-19 vaccines was associated with an increased risk of short-term disease reactivation in a large cohort of pwMS.

Methods

We retrospectively selected 1265 pwMS who received a third booster dose of an mRNA COVID-19 vaccine. Demographic and clinical data were collected, including the presence, number and characteristics of relapses in the 60 days prior to and after the third booster dose.

Results

In the selected cohort, the relapse rate in the two months after administration of the third booster dose of mRNA COVID-19 vaccines did not increase when compared with the prior two months. Indeed, the percentage of pwMS experiencing relapses in the 60 days following the administration of the third booster dose was 2.1%, similar to the percentage recorded in 60 days prior to vaccination, which was 1.9%.

Conclusions

The third booster dose of mRNA COVID-19 vaccines appeared to be safe for pwMS.

Shih HI, Wu CJ, Tu YF, Chi CY (2020) Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. Biomed J 43(4):341–354. https://doi.org/10.1016/j.bj.2020.05.021. (PMID: 32532623)CrossRefPubMedPubMedCentral

Golob JL, Lugogo N, Lauring AS, Lok AS (2021) SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight 6(9):e149187. https://doi.org/10.1172/jci.insight.149187. (PMID: 33822773)CrossRefPubMedPubMedCentral

Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: https://doi.org/10.1056/NEJMoa2034577. PMID: 33301246.

Baden LR, El Sahly HM, Essink B, et al; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384 (5):403–416. doi: https://doi.org/10.1056/NEJMoa2035389. PMID: 33378609.

Karussis D, Petrou P (2014) The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev 13(3):215–224. https://doi.org/10.1016/j.autrev.2013.10.003. (PMID: 24514081)CrossRefPubMed

Zrzavy T, Kollaritsch H, Rommer PS et al (2019) Vaccination in multiple sclerosis: friend or foe? Front Immunol 10:1883. https://doi.org/10.3389/fimmu.2019.01883. (PMID: 31440255)CrossRefPubMedPubMedCentral

Rakusa M, Öztürk S, Moro E, et al (2022) European Academy of Neurology NeuroCOVID-19 Task Force. COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper. Eur J Neurol 29 (8): 2163–2172. doi: https://doi.org/10.1111/ene.15368. PMID: 35460319.

Cabreira V, Abreu P, Soares-Dos-Reis R et al (2021) Multiple sclerosis, disease-modifying therapies and COVID-19: a systematic review on immune response and vaccination recommendations. Vaccines (Basel) 9(7):773. https://doi.org/10.3390/vaccines9070773. (PMID: 34358189)CrossRefPubMed

Achiron A, Dolev M, Menascu S et al (2021) COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by february 2021. Mult Scler 27(6):864–870. https://doi.org/10.1177/13524585211003476. (PMID: 33856242)CrossRefPubMedPubMedCentral

10.

Lotan I, Wilf-Yarkoni A, Friedman Y et al (2021) Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel. Eur J Neurol 28(11):3742–3748. https://doi.org/10.1111/ene.15028. (PMID: 34288285)CrossRefPubMedPubMedCentral

11.

Di Filippo M, Cordioli C, Malucchi S, et al (2022) RIREMS (Rising Researchers in MS) group. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry 93 (4): 448–450. doi: https://doi.org/10.1136/jnnp-2021-327200. PMID: 34408003.

12.

Epstein S, Xia Z, Lee AJ, et al. (2022) Multiple Sclerosis Resilience to COVID-19 (MSReCOV) Collaborative Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data. Mult Scler Relat Disord 57: 103433. Doi: https://doi.org/10.1016/j.msard.2021.103433. PMID: 34923427.

13.

Ciampi E, Uribe-San-Martin R, Soler B et al (2022) Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with multiple sclerosis. Mult Scler Relat Disord 59:103690. https://doi.org/10.1016/j.msard.2022.103690. (PMID: 35182880)CrossRefPubMedPubMedCentral

14.

Czarnowska A, Tarasiuk J, Zajkowska O et al (2022) Safety of Vaccines against SARS-CoV-2 among polish patients with multiple sclerosis treated with disease-modifying therapies. Vaccines (Basel) 10(5):763. https://doi.org/10.3390/vaccines10050763. (PMID: 35632519)CrossRefPubMed

15.

Kong L, Wang X, Chen H et al (2022) Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis. Mult Scler Relat Disord 68:104167. https://doi.org/10.1016/j.msard.2022.104167. (PMID: 36170773)CrossRefPubMedPubMedCentral

16.

Maniscalco GT, Manzo V, Di Battista ME et al (2021) Severe multiple sclerosis relapse after COVID-19 vaccination: a case report. Front Neurol 12:721502. https://doi.org/10.3389/fneur.2021.721502. (PMID: 34447349)CrossRefPubMedPubMedCentral

17.

Nistri R, Barbuti E, Rinaldi V et al (2021) Case report: multiple sclerosis relapses after vaccination against SARS-CoV2: a series of clinical cases. Front Neurol 12:765954. https://doi.org/10.3389/fneur.2021.765954. (PMID: 34744992)CrossRefPubMedPubMedCentral

18.

Quintanilla-Bordás C, Gascón-Gimenez F, Alcalá C et al (2022) Case report: exacerbation of relapses following mRNA COVID-19 vaccination in multiple sclerosis: a case series. Front Neurol 13:897275. https://doi.org/10.3389/fneur.2022.897275. (PMID: 35572939)CrossRefPubMedPubMedCentral

19.

Rinaldi V, Bellucci G, Buscarinu MC et al (2022) CNS inflammatory demyelinating events after COVID-19 vaccines: a case series and systematic review. Front Neurol 13:1018785. https://doi.org/10.3389/fneur.2022.1018785. (PMID: 36530641)CrossRefPubMedPubMedCentral

20.

Levin EG, Lustig Y, Cohen C et al (2021) Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 Months. N Engl J Med 385(24):e84. https://doi.org/10.1056/NEJMoa2114583. (PMID: 34614326)CrossRefPubMed

21.

Capuano R, Bisecco A, Conte M et al (2022) Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod. Mult Scler Relat Disord 60:103724. https://doi.org/10.1016/j.msard.2022.103724. (PMID: 35272145)CrossRefPubMedPubMedCentral

22.

Bar-On YM, Goldberg Y, Mandel M et al (2021) Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 385(15):1393–1400. https://doi.org/10.1056/NEJMoa2114255. (PMID: 34525275)CrossRefPubMed

23.

Capuano R, Prosperini L, Altieri M et al (2023) Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs. Mult Scler 29(7):856–865. https://doi.org/10.1177/13524585231167515. (PMID: 37165941)CrossRefPubMedPubMedCentral

24.

König M, Torgauten HM, Tran TT et al (2022) Immunogenicity and safety of a Third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 Vaccination. JAMA Neurol 79(3):307–309. https://doi.org/10.1001/jamaneurol.2021.5109. (PMID: 35072702)CrossRefPubMedPubMedCentral

25.

Capuano R, Altieri M, Conte M et al (2022) Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod. J Neurol 269(12):6185–6192. https://doi.org/10.1007/s00415-022-11296-4. (PMID: 35879563)CrossRefPubMedPubMedCentral

26.

Dreyer-Alster S, Menascu S, Mandel M et al (2022) COVID-19 vaccination in patients with multiple sclerosis: safety and humoral efficacy of the third booster dose. J Neurol Sci 434:120155. https://doi.org/10.1016/j.jns.2022.120155. (PMID: 35091386)CrossRefPubMedPubMedCentral

27.

Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173. https://doi.org/10.1016/S1474-4422(17)30470-2. (PMID: 29275977)CrossRefPubMed

28.

Ehde DM, Roberts MK, Humbert AT et al (2021) COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: a follow up survey during the initial vaccine rollout in 2021. Mult Scler Relat Disord 54:103163. https://doi.org/10.1016/j.msard.2021.103163. (PMID: 34325399)CrossRefPubMedPubMedCentral

29.

Stastna D, Menkyova I, Drahota J et al (2022) To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection. Mult Scler Relat Disord 65:104014. https://doi.org/10.1016/j.msard.2022.104014. (PMID: 35803085)CrossRefPubMedPubMedCentral

30.

Frahm N, Fneish F, Ellenberger D et al (2023) Frequency and predictors of relapses following SARS-CoV-2 vaccination in patients with multiple sclerosis: interim results from a longitudinal observational study. J Clin Med 12(11):3640. https://doi.org/10.3390/jcm12113640. (PMID: 37297838)CrossRefPubMedPubMedCentral

31.

Stefanou MI, Palaiodimou L, Theodorou A, et al. (2023) Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis. Mult Scler. 13524585221150881. doi: https://doi.org/10.1177/13524585221150881. PMID: 36722184.

32.

Bertozzi A, Mariottini A, Marchi L et al (2023) Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: a monocentric experience. Mult Scler Relat Disord 72:104582. https://doi.org/10.1016/j.msard.2023.104582. (PMID: 36889098)CrossRefPubMedPubMedCentral

33.

Farez MF, Correale J (2011) Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 258(7):1197–1206. https://doi.org/10.1007/s00415-011-5984-2. (PMID: 21431896)CrossRefPubMed

34.

Buljevac D, Flach HZ, Hop WC et al (2002) Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125(Pt 5):952–960. https://doi.org/10.1093/brain/awf098. (PMID: 11960885)CrossRefPubMed

Title: SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose
Authors: Massimiliano Di Filippo
Diana Ferraro
Paolo Ragonese
Luca Prosperini
Giorgia Teresa Maniscalco
Antonio Gallo
Paola Cavalla
Lorena Lorefice
Viviana Nociti
Elena Di Sabatino
Marinella Clerico
Clara Guaschino
Marta Radaelli
Roberta Fantozzi
Fabio Buttari
Alice Laroni
Alberto Gajofatto
Massimiliano Calabrese
Simona Malucchi
Damiano Paolicelli
Giovanna De Luca
Valentina Tomassini
Roberta Lanzillo
Marcello Moccia
Claudio Solaro
Eleonora Cocco
Claudio Gasperini
Carla Tortorella
the RIREMS (Rising Researchers in MS) group
Publication date: 03-11-2023
Publisher: Springer Berlin Heidelberg
Keywords: Vaccination
Multiple Sclerosis
COVID-19 Vaccination
SARS-CoV-2
COVID-19
Published in: Journal of Neurology / Issue 1/2024
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-12034-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose

Abstract

Background

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Persistent cognitive slowing in post-COVID patients: longitudinal study over 6 months

Phenotype-driven reanalysis reveals five novel pathogenic variants in 40 exome-negative families with Charcot–Marie–Tooth Disease

A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution

Understanding the genetic mechanisms and cognitive impairments in Down syndrome: towards a holistic approach

Subacute transverse myelitis of possible vasculitic origin after SARS-CoV2 and Varicella-Zoster virus infections: a case report

Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome